Neurocode Launches Groundbreaking pTau217 Blood Test for Alzheimer’s Disease Clinical Diagnosis

On March 4, 2024, Neurocode USA, Inc, a specialized clinical laboratory that offers world-class testing solutions for neurological disorders, announced the clinical launch of ALZpath Dx, an innovative and novel blood test that can be used in the screening, diagnosis, and monitoring of Alzheimer's disease (AD) based on circulating level of pTau217 in the blood. Neurocode is the first laboratory in the United States to make this test available as a Laboratory Developed Test (LDT) for clinical diagnostic use, clinical trials, and other research purposes.

Login Or Register To Read Full Story